Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous cluster-immunotherapy with CLUSTOID D. pteronyssinus in house dust mite allergy
2022-001610-19Phase 2Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Oct 2022
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dermatophagoides pteronyssinus in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by ROXALL Medizin GmbH. Started Oct 2022; status: completed.
02
Drugs
dermatophagoides pteronyssinus
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2022-001610-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001610-19.